The Vestibular Schwannoma market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Vestibular Schwannoma: An Overview
A vestibular schwannoma (also known as acoustic neuroma, acoustic neurinoma, or acoustic neurilemoma) is benign, usually, a slow-growing tumor developed from the balance and hearing nerves supplying the inner ear. The tumor comes from an overproduction of Schwann cells that generally wrap around nerve fibers like onion skin to help support and insulate nerves.
It is classified as sporadic unilateral or hereditary bilateral. Sporadic Unilateral acoustic neuromas affect only one ear. It is the most common type of VS. This tumor may develop at any age. It most often happens between the ages of 30 and 60. Hereditary Bilateral acoustic neuromas: this type affects both ears and is inherited, and it is caused by a genetic problem called neurofibromatosis-2 (NF2).
Vestibular Schwannoma Market Key Facts
-
According to the Central Brain Tumor Registry of the United States (US), from 2004 to 2010, the overall incidence of Vestibular Schwannoma was 1.09 per 100,000/year. This incidence increased with age to a peak of 2.93 per 100,000/year in the age group 65–74 years without gender difference.
-
A recent analysis of the Surveillance, Epidemiology and End Results database in the US, including a total of 9,782 Vestibular Schwannoma patients among 822 million person-years revealed the median annual disease incidence to be lowest among black and Hispanic and highest among Caucasian populations (p < 0.001) (Roland Goldbrunner et al.)
-
According to Facial Palsy, 13 people in every million are diagnosed each year with a vestibular schwannoma in the UK.
-
As per DelveInsight, Sporadic Unilateral acoustic neuromas are more common than Bilateral acoustic neuromas in the 7MM.
As per DelveInsight, among 7MM, the United States accounted for the highest market size of Vestibular Schwannoma in comparison to EU5 and Japan.
There are no medical therapies that are presently approved by the US FDA and EMA, representing an urgent and unmet clinical need for the treatment of Vestibular Schwannoma. However, the increasing research in the therapeutics domain is expected to change the market dynamics.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Vestibular Schwannoma market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the Vestibular Schwannoma market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Vestibular Schwannoma Epidemiology
The epidemiology section covers insights into the historical and current Vestibular Schwannoma patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Vestibular Schwannoma Epidemiology Segmentation
-
Total Incident/Prevalent Cases of Vestibular Schwannoma
-
Type-specific Cases of Vestibular Schwannoma
Vestibular Schwannoma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Vestibular Schwannoma market or expected to get launched in the market during the study period. The analysis covers Vestibular Schwannoma market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Vestibular Schwannoma Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Get the PDF Sample of the Report:- https://www.delveinsight.com/sample-request/vestibular-schwannoma-market
Vestibular Schwannoma Therapeutics Analysis
Currently, there are no FDA-approved drugs for vestibular schwannomas or the associated hearing loss. Therefore, an unmet medical need to discover drugs with minimal adverse effects to treat this tumor and reduce or obviate the need for surgery and radiation.
Further, by using novel computational strategies to capitalize on emerging high-throughput genomic information, it is possible to identify safe drugs with evidence-based potential for repurposing in other conditions, which can eliminate the need for a Phase I safety trial and expedite Phase II efficacy trials.
At present, companies such as Genentech, AstraZeneca, Takeda, and others are working to develop therapies for the treatment of Vestibular Schwannoma.
Some of the key therapies in the Vestibular Schwannoma market include:
-
Selumetinib – Selumetinib is being developed by AstraZeneca. It is an oral selective inhibitor of MAPK kinase (MEK) 1 and 2. MEK 1 and 2 are dual-specificity kinases that are essential mediators in the activation of the RAS/RAF/MEK/ERK pathway, are often upregulated in various cancer cells, and are drivers of diverse cellular responses, including proliferation.
-
Brigatinib – Takeda is working on Brigatinib (AP26113). Brigatinib is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type.
Get More Detailed Insights into the Emerging Therapies & Key Companies:- https://www.delveinsight.com/sample-request/vestibular-schwannoma-market
Table of Content
1. Key Insights
2. Executive Summary
3. Vestibular Schwannoma Competitive Intelligence Analysis
4. Vestibular Schwannoma Market Overview at a Glance
5. Vestibular Schwannoma Disease Background and Overview
6. Vestibular Schwannoma Patient Journey
7. Vestibular Schwannoma Epidemiology and Patient Population
8. Vestibular Schwannoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Vestibular Schwannoma Unmet Needs
10. Key Endpoints of Vestibular Schwannoma Treatment
11. Vestibular Schwannoma Marketed Products
12. Vestibular Schwannoma Emerging Therapies
13. Vestibular Schwannoma Seven Major Market Analysis
14. Attribute Analysis
15. Vestibular Schwannoma Market Outlook (7 major markets)
16. Vestibular Schwannoma Access and Reimbursement Overview
17. KOL Views on the Vestibular Schwannoma Market.
18. Vestibular Schwannoma Market Drivers
19. Vestibular Schwannoma Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The table of contents is not exhaustive; the final content may vary.
Request Sample Report here:- https://www.delveinsight.com/sample-request/vestibular-schwannoma-market
Other Latest Reports By DelveInsight
DelveInsight’s “Pars Plantis Market” report delivers an in-depth understanding of the historical and forecasted epidemiology, the Metrorrhagia market size and shares analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan) as well as the emerging therapies and key companies in the therapeutic domain.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/